

CLINUVEL

ASX ANNOUNCEMENT

Melbourne, Australia, 28 August 2025

ASX: CUV | Börse Frankfurt: UR9 | ADR Level I: CLVLY

CLINUVEL delivers ninth consecutive year of revenues growth and profit

Key Highlights, Year Ending 30 June 2025

Consolidated Entity	30 June 2025	30 June 2024	Change YOY
Total Revenues	\$105,300,000	\$95,306,000	Up 10%
Total Expenses	\$53,747,000	\$44,627,000	Up 20%
Net Profit before income tax	\$51,553,000	\$50,679,000	Up 2%
Net Profit after income tax expense	\$36,173,000	\$35,636,000	Up 2%
Cash Reserves	\$224,106,000	\$183,868,000	Up 22%
Basic Earnings per Share	\$0.72	\$0.72	Up 1%
Net Tangible Assets backing per Share	\$4.77	\$4.02	Up 19%
Dividend distribution per Share	\$0.05	\$0.05	Stable

All figures are reported in Australian dollars for the financial years ending 30 June., rounded to the nearest \$1,000.
Total Revenues include interest and other income.
Cash Reserves equal Cash and Cash Equivalents plus Cash Held on Term Deposit.
Refer to the Appendix 4E Preliminary Final Report released to the Australian Securities Exchange for details.

CLINUVEL has announced its ninth consecutive profit of \$51.6 million before tax and \$36.2 million after tax for the fiscal year ending 30 June 2025 (FY2025). Revenues grew by 10% to \$105.3 million in FY2025 from sales of SCENESSE® (afamelanotide 16mg) to treat erythropoietic protoporphyria (EPP) patients, primarily in Europe and the USA. Expenses grew by 20% to \$53.7 million in FY2025, reflecting the Company's direct and indirect costs associated with its clinical program for vitiligo.


"The CLINUVEL team has delivered what it set out to achieve in FY2025: continued commercial growth while accelerating our Phase III clinical program for vitiligo in a cost-controlled manner," CLINUVEL's Chief Financial Officer, Peter Vaughan said. "This year's result sees us deliver a ninth year of profits from the commercial distribution of SCENESSE® for EPP.

"All of our key financial metrics – revenues, profit, re-investment in the business and asset growth – continue to increase year-on-year, providing a strong basis for a sustainable biopharmaceutical group and enabling us to expedite our objectives for the revenues and growth of tomorrow," Mr Vaughan added.

Consistent Growth Translates to Financial Strength

Revenues grew by 10% in FY2025, driven by robust demand from EPP patients for SCENESSE® treatment and higher interest income. Reflecting consistent demand for treatment since the commencement of commercial operations, CLINUVEL has achieved a nine-year CAGR for revenues of 35%. Controlled expenses to support business expansion resulted in a corresponding CAGR for expenses of 20%.


Net profit before income tax increased by 2% to \$51.6 million and after income tax increased by 2% to \$36.2 million.



CLINUVEL has evolved over the past nine years by integrating critical operational functions in-house, including commercial distribution, regulatory compliance, product and clinical R&D, and communications, branding & marketing (CBM). This approach is reflected in FY2025 expenses with increased personnel related expenses (31%) supporting a wide range of in-house activities, including higher clinical and non-clinical development expenses (215%) and CBM expenses (100%).

In FY2021 the Company issued a five-year expense plan to the end of FY2025 of \$175.0 million, net of CBM activities. Cumulative expenses in the five years to 30 June 2025 were \$171.2 million, testament to CLINUVEL's planning and expense management.

CLINUVEL's strengthened balance sheet holds net assets of \$240.8 million as of 30 June 2025. Positive annual net cash inflow from commercial operations of \$41.1 million have built cash reserves, enabling the Company to self-finance its diversification plans and provide a buffer to manage risks in a volatile macroeconomic environment. Cash reserves increased by 22% to \$224.1 million during FY2025.



Eighth Consecutive Annual Dividend

The CLINUVEL Board has declared an annual franked dividend of \$0.05 per ordinary share following the FY2025 financial results – this is the eighth consecutive annual dividend and fourth fully franked. Subject to the Company maintaining sufficient cash reserves, the key dates for the dividend are:

- | | | |
|------|-------------------|--------------------|
| I. | Ex-dividend date: | 04 September 2025 |
| II. | Record date: | 05 September 2025 |
| III. | Payment date: | 19 September 2025. |

Dividends are available to both Australian and overseas registered shareholders, including holders of CLINUVEL's Level I American Depositary Receipt program. Prior to the record date, shareholders are encouraged to confirm their shareholder information, including payment election details, with the Company's share registry – Computershare.

CLINUVEL Briefing

CLINUVEL will host an investor and analyst webinar at 18:00 AEST today to review the results achieved in FY2025. Participants can register using the link below:

INVESTOR WEBINAR

28 August 2025

18:00-18:30 AEST (10:00-10:30 CEST)

To participate, please register using this link:

[CLINUVEL Investor Webinar](#)

Questions may be tabled as you register, and during the webinar.

– END –

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL I: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Media Enquiries

Monsoon Communications

Mr Rudi Michelson, 61 411 402 737, rudim@monsoon.com.au

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran's Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2025 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: mail@clinuvel.com

Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

